Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110 070, India.
Department of Pediatrics, S N Medical College, Agra, 282 002, India.
Indian J Gastroenterol. 2023 Apr;42(2):209-218. doi: 10.1007/s12664-022-01328-2. Epub 2023 Apr 14.
To evaluate the response and outcome with prolonged intravenous antibiotics including home-based intravenous antibiotics in children with intractable cholangitis (IC) after Kasai portoenterostomy (KPE) for biliary atresia (BA).
A retrospective review of treatment and outcome of children with IC post KPE (no resolution after four weeks of antibiotics) was done between 2014 and 2020. A protocol-based antibiotic regimen was used based on sensitivity and hospital antibiogram. Children afebrile for more than three days were discharged on home intravenous antibiotics (HIVA).
Twenty children with IC were managed with prolonged antibiotic regimen, including HIVA. All patients were initially listed for liver transplantation (LT) with indication being IC (n = 20) with portal hypertension (n = 12). Seven patients had bile lakes of which four underwent percutaneous transhepatic biliary drainage. Bile culture grew Klebsiella in four and Escherichia coli and Pseudomonas one each. There were eight children with IC who had positive blood culture with most of these organisms being gram-negative (Escherichia coli: 5, Klebsiella pneumoniae: 2, Enterococcus: 1). Median duration of antibiotics was 58 days (interquartile range [IQR] 56-84). Median follow-up period post cholangitis was three years (IQR 2-4). Following treatment, 14 patients were successfully delisted from LT waitlist and are presently jaundice-free. Two of the five patients undergoing LT died of sepsis. One patient died awaiting LT.
Timely and aggressive step-up antibiotic regimen may successfully treat IC and prevent/delay LT. HIVA provides a cost-effective and comfortable environment for a child which might improve compliance with intravenous antibiotics.
评估难治性胆管炎(IC)患儿在接受胆道闭锁(BA)Kasai 门腔分流术后(抗生素治疗 4 周后仍未缓解)延长静脉内抗生素治疗(包括家庭静脉内抗生素治疗)的反应和结局。
对 2014 年至 2020 年期间接受难治性胆管炎治疗的患儿进行了回顾性研究,分析其治疗和结局。根据敏感性和医院抗生素图谱,采用基于方案的抗生素治疗方案。如果患儿连续 3 天以上不发热,即可出院接受家庭静脉内抗生素治疗。
20 例 IC 患儿接受了延长抗生素治疗方案,包括家庭静脉内抗生素治疗。所有患者最初均因 IC(n=20)和门静脉高压(n=12)而被列入肝移植(LT)名单。7 例患儿有胆湖,其中 4 例行经皮经肝胆管引流术。4 例胆汁培养出克雷伯菌,1 例大肠埃希菌和 1 例铜绿假单胞菌。8 例 IC 患儿血培养阳性,其中大多数为革兰氏阴性菌(大肠埃希菌:5 株,肺炎克雷伯菌:2 株,肠球菌:1 株)。抗生素治疗的中位持续时间为 58 天(IQR 56-84)。胆管炎后中位随访时间为 3 年(IQR 2-4)。治疗后,14 例患者成功从 LT 等待名单中除名,目前已无黄疸。5 例行 LT 的患者中,有 2 例死亡,1 例死于败血症。1 例患者在等待 LT 时死亡。
及时、积极的升级抗生素治疗方案可能成功治疗 IC,并预防/延迟 LT。家庭静脉内抗生素治疗为患儿提供了一种经济有效的舒适环境,可能提高患儿对静脉内抗生素的依从性。